Lakefront Biotherapeutics NV LKFT
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Lakefront Biotherapeutics NV shares you hold and we'll calculate your dividend payments:
Sign up for Lakefront Biotherapeutics NV and we'll email you the dividend information when they declare.
Add Lakefront Biotherapeutics NV to receive free notifications when they declare their dividends.
Your account is set up to receive Lakefront Biotherapeutics NV notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Lakefront Biotherapeutics NV dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0¢ | — |
| 2007 | 0.0¢ | 0% |
| 2008 | 0.0¢ | 0% |
| 2009 | 0.0¢ | 0% |
| 2010 | 0.0¢ | 0% |
| 2011 | 0.0¢ | 0% |
| 2012 | 0.0¢ | 0% |
| 2013 | 0.0¢ | 0% |
| 2014 | 0.0¢ | 0% |
| 2015 | 0.0¢ | 0% |
| 2016 | 0.0¢ | 0% |
| 2017 | 0.0¢ | 0% |
| 2018 | 0.0¢ | 0% |
| 2019 | 0.0¢ | 0% |
| 2020 | 0.0¢ | 0% |
| 2021 | 0.0¢ | 0% |
| 2022 | 0.0¢ | 0% |
| 2023 | 0.0¢ | 0% |
| 2024 | 0.0¢ | 0% |
| 2025 | 0.0¢ | 0% |
| 2026 | Sign Up Required | |
Lakefront Biotherapeutics NV Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 13 June 2025
- 52 Week Low
- 0.0% on 13 June 2025
- Next Ex-Div-Date Countdown
- Sign Up Required
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- Netherlands
- Share Price
- €24.94 (yesterday's closing price)
- Shares in Issue
- 66 million
- Market Cap
- €1.6bn
- 0
- Market Indices
- AEX 25, STOXX600
- Financial Calendar URL
- Sign Up Required
- Home Page URL
- https://lakefrontbio.com/
